αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib

• DOI: 10.1136/jitc-2020-001162
• Publication Date: 2021-02-15T18:25:11Z
• Authors: Juemin Fang; Na Ding; Xianling Guo; Yan Sun; Zhiwei Zhang; Bailu Xie; Zhong Li; Hui Wang; Wei Mao; Zhicai Lin; Fei Qin; Min Yuan; Wenqi Chu; Huanlong Qin; Qijun Qian; Qing Xu
• Keywords: Apatinib; Mesothelin

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced/refractory lacks effective targeted therapies due to immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found be highly expressive most EOC. Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells immune checkpoint blockades as well apatinib, an anti-angiogenic drug, have used patients with refractory cancer. Apatinib was reported promote infiltration CD8 + lung However, combination therapy CAR-T secreting anti-PD-1 antibody apatinib EOC not reported. Case presentation Here we report a case patient who had relapsed after multiline chemotherapy. The received autologous that contained sequences encoding single-chain variable fragments specific for full-length PD-1 (αPD-1). modified were called αPD-1-mesoCAR-T cells. After infusion, copy number secretion increased blood. By application multimodality tracking, MRI liver showed shrinkage metastatic nodules from average diameter 71.3–39.1 mm at month 2. achieved partial response survived more than 17 months. IL-6 levels fluctuated baseline 2–4-folds treatment, but side effects mild only grade 1 hypertension fatigue. Conclusion cell combined demonstrates potential therapeutic effect on advanced Trial registration NCT03615313 .